Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

ClinicalTrials.gov ID: NCT03941093

Public ClinicalTrials.gov record NCT03941093. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic cancer.

Study identification

NCT ID
NCT03941093
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Kyntra Bio
Industry
Enrollment
284 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 9, 2019
Primary completion
Jun 10, 2024
Completion
Jun 10, 2024
Last update posted
Nov 4, 2024

2019 – 2024

United States locations

U.S. sites
32
U.S. states
20
U.S. cities
31
Facility City State ZIP Site status
St. Joseph's Hospital and Medical Cancer Center Phoenix Arizona 85004
UC San Diego Moores Cancer Center La Jolla California 92037
UCLA Los Angeles California 90095
UC Davis Comprehensive Cancer Center Sacramento California 95817
Yale New Haven Hospital New Haven Connecticut 06510
Elmhurst Memorial Hospital - Nancy W. Knowles Cancer Center Elmhurst Illinois 60126
Edward Cancer Center Naperville Illinois 60540
Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis Indiana 48202
University of Kansas Hospital Westwood Kansas 66205
Norton Cancer Institute, Audubon Hospital Campus Louisville Kentucky 40217
Maine Health Cancer Care South Portland Maine 04106
University of Massachusetts Worcester Massachusetts 01655
University of Michigan Ann Arbor Michigan 48109
Karmanos Cancer Institute Detroit Michigan 48201
Saint Luke's Hospital Kansas City Missouri 64111
University of Nebraska Medical Center Omaha Nebraska 68105
New Mexico Cancer Care Alliance Albuquerque New Mexico 87131
NYU Langone Health New York New York 11735
Stony Brook University Stony Brook New York 11794
SUNY Upstate Medical University Syracuse New York 13210
University of Cincinnati Medical Center Cincinnati Ohio 45219
Ohio State University Columbus Ohio 43210
Thomas Jefferson University Philadelphia Pennsylvania 19107
Allegheny General Hospital Pittsburgh Pennsylvania 15212
Reading Hospital McGlinn Cancer Institute West Reading Pennsylvania 19611
Baylor College of Medicine Houston Texas 77030
Baylor Scott & White Medical Center Temple Texas 76508
Renovatio Clinic The Woodlands Texas 77380
Inova Schar Cancer Institute Fairfax Virginia 22031
Virginia Mason Medical Center Seattle Washington 98101
University of Washington Medical Center Seattle Washington 98195
West Virginia University Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03941093, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 4, 2024 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03941093 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →